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Background: Since post-infarction heart failure (HF) determines a great morbidity and mortality, and given the
physiopathology implications of advanced glycation end products (AGE) in the genesis of myocardial dysfunction, it
was intended to analyze the prognostic value of these molecules in order to predict post-infarction HF
development.
Methods: A prospective clinical study in patients after first acute coronary syndrome was conducted. The follow-up
period was consisted in 1 year. In 194 patients consecutively admitted in the coronary unit for myocardial infarct
fluorescent AGE levels were measured. The association between glycaemic parameters and the development of
post-infarction HF were analyzed in those patients. Finally, we identified the variables with independent predictor
value by performing a multivariate analysis of Hazard ratio for Cox regression.
Results: Eleven out of 194 patients (5.6%) developed HF during follow-up (median: 1.0 years [0.8 - 1.5 years]). Even
though basal glucose, fructosamine and glycated haemoglobin were significant predictive factors in the univariate
analysis, after being adjusted by confounding variables and AGE they lost their statistical signification. Only AGE
(Hazard Ratio 1.016, IC 95%: 1.006-1.026; p<0,001), together with NT-proBNP and the infarct extension were
predictors for post-infarction HF development, where AGE levels over the median value 5-fold increased the risk of
HF development during follow-up.
Conclusions: AGE are an independent marker of post-infarction HF development risk.
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Heart failure (HF) is a major cause of morbidity and
mortality. Its incidence is increasing, in part as a second-
ary effect of the growing number of myocardial infarc-
tion survivor patients due to advances in drug therapy
and cardiovascular interventions [1]. After myocardial
infarction, physiological and anatomical ventricular* Correspondence: ezequiel.alvarez@usc.es
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distribution, and reproduction in any mediumchanges occur. Left ventricular dilatation, eccentric
hypertrophy, thinning of myocardial wall in the area of
the scar and eventually left ventricular geometry alter-
ation are aspects that define this process [2]. These
changes are collectively known as ventricular remodel-
ling, and they start a little after the myocardial infarction
(even before any symptoms has been shown) as a pro-
gressive process that involves a worse prognosis for
patients [3].
Ventricular remodelling is based on a neurohormonal
model in which compensatory mechanisms of hormones
and peptides acting in the kidney, as well as the periph-
eral vascular system and myocardium are implicated [4].ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cytokines, growth factors and reactive oxygen species
production [5], which contributes to perpetuate ven-
tricular dysfunction and could have important implica-
tions for prognosis.
Recent studies have shown the implication of hyper-
glycaemia in the development of HF [6], establishing an
independent prognostic value for glycated haemoglobin
(HbA1c) predicting the risk of HF in both diabetic and
non-diabetic patients [7,8]. HbA1c is only an early glyca-
tion product [9]. However, there are no human studies
demonstrating pathophysiological or prognostic implica-
tions for advanced glycation end products (AGE) in
post-infarction HF.
AGE levels are increased in pro-inflammatory and oxi-
dative stress states [10,11]. Either by their direct inter-
action with proteins, such as extracellular collagen, or by
its interaction with its receptor (RAGE), AGE can lead
to diastolic, systolic and vascular dysfunction [12].
Therefore, it could be hypothesized that, instead of act-
ing as a single marker, these glycation end products
might play an important role in post-infarction HF.
In this work, we analyze the prognostic value of both
early (fructosamine and HbA1c) and advanced (AGE)
glycation products in the development of post-infarction
HF.
Subjects and methods
Study population
This is a prospective single centre study including all
consecutive patients admitted with acute myocardial in-
farction (based on the universal definition of infarction
[13]) in the coronary care unit from our hospital be-
tween October 2009 and January 2011, and who had sur-
vived to the acute coronary event during the hospital
stay. Exclusion criteria included the presence of preg-
nancy, a history of HF, cardiomyopathy, moderate-severe
valve disease, previous coronary artery disease, stroke,
peripheral arterial disease, renal dysfunction on admis-
sion (defined by a rate of glomerular filtration rate by
MDRD-4 <60 ml/min/1.73 m2), chronic liver disease,
autoimmune or chronic inflammatory diseases, recent
(last 3 weeks) infectious process, recent (last 3 weeks)
treatment with corticosteroids or anti-inflammatory
drugs, known tumour processes at the time of inclusion
in the study, blood disorders and hospital admissions in
the last month. As a result, 194 patients were included
in the study after informed consent, according to rules
approved by the Clinical Research Ethics Committee of
Galicia (Spain).
Protocol
The protocol study included a complete medical history,
serum biochemistry and echocardiography within 24hours. The diagnosis of diabetes mellitus (DM) was
based on the latest diagnostic criteria established by the
American Diabetes Association [14]. Left ventricular
ejection fraction (LVEF) ≤ 45% was considered as
depressed. Therapeutic strategy and pharmacological
treatment were prescribed according to Clinical Practice
Guidelines published by the European Society of Cardi-
ology [15,16], always based on clinical judgment of car-
diologists responsible for the patients in the coronary
care unit.
Laboratory parameters
AGE were measured by fluorescence spectrometry
(Munch’s method [17]), taking into account the fluores-
cent property of some AGE, which emit strong fluores-
cence at 460 nm after being subjected to an excitation
source at 360 nm. For this purpose, using samples of
plasma of 80 μl in multiwell dark plates, AGE were mea-
sured by duplicate in a multi-mode reader (Synergy 2,
Biotek) with a coefficient of variation of less than 8%.
The results of these measurements were expressed in
arbitrary fluorescence units (AU). Glycated haemo-
globin (HbA1c) was determined by high performance
liquid chromatography and fructosamine was mea-
sured by the enzymatic method GlyPro (with kits
from Genzyme). NT-proBNP was measured by ELISA
and cardiac troponin I was measured using an ultra-
sensitive kit.
Monitoring and events
Patients were followed for a average period of 367.5 days
(301.8 to 530.5). During follow-up, 4 patients (2.1%)
died. Primary endpoint was defined as the readmission
by HF, considering as such the need for hospitalization
or stay in emergency room at least 24 hours and/or need
for intravenous diuretic therapy. The diagnosis of HF
were stabilized by a cardiologist blind to the study, based
on clinical criteria and a structural and/or functional
heart anomaly detectable by echocardiography, accord-
ing to the diagnostic criteria for HF proposed by the
European Society of Cardiology [18].
Statistical analysis
In order to accomplish the analysis of data, we used SPSS
(SPSS Inc, Chicago, Illinois, version 17.0). Categorical vari-
ables were expressed as frequencies and percentages. With
regard to continuous variables, the assumption of normal-
ity was tested with the Kolmogorov-Smirnov test. The
variables that follow a normal distribution were expressed
as mean ± standard deviation. The remaining variables
were expressed as median and interquartile range. The as-
sociation between categorical variables were tested using
the Chi-square test and the relationship between quantita-
tive variables was determined by Pearson correlation. The
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ables was carried out with the Student’s t-test (when nor-
mality condition was reached) or the non-parametric "U"
test by Mann–Whitney (if the no-normal condition was
the one satisfied). To study the independence of the asso-
ciation between fluorescent AGE and post-infarction HF
development, those variables with clinical or statistical sig-
nificance for univariate analysis were included in a Cox re-
gression model (backward stepwise Hazard analysis).
Since the number of events was low (n = 11), variables
that could lead to interactions (eg, fructosamine with gly-
cated hemoglobin) were avoided in order to improve ac-
curacy getting results. Based on this, we took into account
the following variables for Hazard Ratio analysis: age
(years), diabetes mellitus, heart rate (bpm), depressed left
ventricular ejection fraction (LVEF≤45%), haemoglobin on
admission (g/dL), troponin I peak (ng/dL), NTproBNP
(for 100 pg/mL), HbA1c (%) and fluorescent AGE (AU).
We considered significant p values < 0.05.Results
Baseline characteristics and clinical considerations
In Table 1, demographic, clinical and analytical character-
istics of patients, as well as their therapeutic manipula-
tions, have been summarized. Based on HF development
during follow-up, patients were classified in two groups.
As can be seen, at the time of hospital admission, patients
who developed post-infarction HF presented worst killip
class, increased heart rate, greater myocardial damage
(expressed as higher troponin I peak) and higher systolic
ventricular dysfunction, lower haemoglobin levels and
increased serum concentration of NT-proBNP and gly-
caemic control parameters (although there were no differ-
ences depending on the presence or absence of DM).
There were no significant differences neither in percutan-
eous intervention nor in coronary artery bypass grafting.
The pharmacological therapy was very similar in both
groups. Only one difference was observed; the anti-
aldosterone drugs were more used in patients with post-
infarction HF, secondary to the existence of higher sys-
tolic ventricular dysfunction.Clinical significance of glycation parameters
Glucose, fructosamine and HbA1C presented a strong
interrelationship. However, fluorescent AGE did only
show correlation with fructosamine (r = 0.169; p =
0.045). There was no relationship neither between fluor-
escent AGE and HbA1c (r = 0.144; p = 0.061) nor be-
tween AGE and glucose (r = 0.108; p = 0.136).
Considering the association with DM (Table 2), all para-
meters were significantly increased in diabetic patients;
only fluorescent AGE presented the same value in dia-
betic and non-diabetic patients.In Table 3, patients have been grouped based on high
and low levels of early (HbA1c) and late (fluorescent
AGE) glycation products. As can be seen, patients with
increased levels of HbA1c presented a higher cardiovas-
cular risk profile (older, higher BMI and percentage of
DM, hypertension and dyslipidemia). This resulted in a
greater percentage of multivessel disease, with a trend
toward a higher atrial fibrillation percentage and higher
Killip class on admission. As opposed to this, increased
levels of fluorescent AGE were only associated with a
higher percentage of hypertension and a lower rate of
myocardial infarction with ST segment elevation. No
correlation with DM, multivessel disease or ventricular
dysfunction was observed, considering median as the
cut-off point (for HbA1c and fluorescent AGE).
Glycation parameters and their association with post-
infarction HF
Figure 1 shows the association of glucose, fructosamine,
HbA1c and AGE plasmatic basal levels with HF develop-
ment during follow-up. Eleven patients developed HF
during follow-up (Table 4). A multivariate analysis was
performed in order to determine the behaviour of each
independent predictor of glycaemic control parameters
(Table 5). As a means to get this, variables that were sig-
nificantly associated with post-infarction HF develop-
ment were taken into account (Table 1). Moreover, those
variables with clinical significance documented on previ-
ous studies (GISSI [1] and PEACE [19]) were also
included, even though they did not present statistical
significance. After performing the multivariate analysis
and adjusting for confounding variables, results, as
reflected in Table 5, showed that troponin I peak, NT-
proBNP levels and fluorescent AGE were the only vari-
ables that remained as independent predictors of post-
infarction HF development. HbA1c lost its predictive
value after being adjusted by the presence of DM and
fluorescent AGE, among other variables. In and identical
manner, two alternative models of the same multivariate
analysis were developed. On one of these analyses,
HbA1c was replaced by fructosamine and on the other
one by glucose levels at admission. Parameters were
separated in the analysis to avoid interaction between
those variables and HbA1c, given the strong positive
correlation showed. Results were similar to the ones
obtained for HbA1c, remaining only fluorescent AGE,
together with troponin I peak and NT-proBNP, as inde-
pendent predictors of HF development. The HR ratio for
fructosamine was 1.007 (95% CI: 0.989 to 1.025, p =
0.440) and for basal glucose 1.003 (95% CI: 0.991 to
1.014, p = 0.666). Figure 2 shows the fitted curves for
HF development during follow-up where AGE and
HbA1c values were above the median. As can be
observed, high levels of AGE, but not high levels of
Table 1 Baseline characteristics of the study population, stratified by groups according to whether or not they
developed HF during the follow-up period
Total Heart failure
YES NO p
Demographic data
Age (years) 62.8 ± 13.3 67.4 ± 11.6 62.6 ± 13.4 0.244
Female, % 24.7 27.3 35.0 0.841
Medical history
BMI (Kg/m2) 27.0±3.3 25.7±3.9 27.1±3.5 0.225
Current smoking, % 34.5 27.3 35.0 0.703
Diabetes, % 26.8 36.4 26.2 0.461
Hypertension, % 47.9 63.6 47.0 0.283
Dyslipidemia, % 44.8 45.5 44.7 0.957
On admission data
STEMI, % 52.1 72.7 50.8 0.158
Killip class ≥ II, % 13.9 36.4 12.6 0.027
Systolic blood pressure (mmHg) 137.0 ± 26.4 135.8 ± 25.7 137.1 ± 26.5 0.881
Heart rate (bpm) 75.2 ± 18.8 93.8 ± 16.4 74.1 ± 18.4 0.001
Atrial fibrillation, % 8.2 18.2 7.7 0.217
Haemoglobin (g/dL) 14.3 ± 1.6 13.1 ± 1.5 14.4 ± 1.6 0.011
Leukocytes (103/μL) 9.8 ± 4.0 9.6 ± 4.1 10.9 ± 4.0 0.314
Creatinine (mg/dL) 0.95 ± 0.15 0.99 ± 0.12 0.95 ± 0.16 0.396
Laboratory parameters
TPI peak (ng/dL) 17.1 (5.6-68.2) 114.7 (23.5-171.5) 15.3 (5.2-59.4) 0.024
NT-proBNP (pg/mL) 801.5 (352.7-1779.3) 2938.0 (1400.0-3655.0) 769.5 (320.5-1663.2) 0.011
Glycation products
Glucose (mg/dL) 152.9 ± 74.1 203.0± 96.7 149.9 ± 71.7 0.021
Fructosamine (mg/dL) 192.4 ± 71.5 243.5 ± 95.3 188.5 ± 68.2 0.019
HbA1c (%) 6.2 ± 1.4 7.1 ± 2.3 6.1 ± 1.3 0.017
AGE fluorescent (AU) 57.3 ± 45.0 95.9 ± 83.1 54.9 ± 40.9 0.003
Procedural characteristics
LVEF ≤ 45%, % 19.6 54.5 17.5 0.003
Multivessel disease, % 52.1 63.6 51.4 0.429
PCI, % 82.0 72.7 82.5 0.412
CABG, % 5.7 9.1 5.5 0.617
Complete revascularization, % 80.2 37.5 82.3 0.002
Medical treatment
Acetylsalicylic acid 100.0 100.0 100.0 -
Clopidogrel 99.0 98.9 100.0 0.722
Anti-IIb-IIIA 19.1 9.1 19.7 0.386
B-blockers 86.1 90.8 85.8 0.634
ACE Inhibitors-ARAII 89.7 89.6 90.9 0.767
Anti-aldosterone medication 20.1 63.6 17.5 <0.001
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Table 1 Baseline characteristics of the study population, stratified by groups according to whether or not they
developed HF during the follow-up period (Continued)
Statins 94.9 90.0 95.2 0.463
Insulin 5.7 18.2 4.9 0.065
Oral anti-diabetics 11.8 20.0 11.3 0.408
AGE: advanced glycation end products; ARAII: angiotensin II receptor antagonists; BMI: body mass index; CABG: coronary artery bypass graft; HbA1c: glycated
haemoglobin; LVEF: left ventricular ejection fraction; STEMI: ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; ACE: angiotensin-
converting enzyme; NT-proBNP: N-terminal fragment of brain natriuretic peptide; TPI: troponin I peak.
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opment (HR 5.467, 95% CI: 1.015 to 29.443, p = 0.048).
Discussion
The most important finding of our study was that fluor-
escent AGE [detectable in plasma by 360/460 nm (exc./
em.) fluorescence] is an independent and predictive bio-
marker for HF development risk after an acute myocar-
dial infarct, whereas glycation precursors such as
glycated haemoglobin lost their predictive value after a
multivariate statistical adjustment. High AGE levels
(over the median value) 5-fold increased the risk of post-
infarction HF during the follow-up period, regardless of
age, DM presence and glycaemic control, infarct’s ser-
iousness (ventricle dysfunction and troponin elevation)
and other biomarkers such as NT-proBNP. Although
HbA1c, fructosamine and basal glucose, were signifi-
cantly associated with a higher post-infarction HF rate
in the univariate analysis, they lost their significance
after being adjusted with other confounding variables,
like AGE, in the multivariate analysis.
Within the last few years it has been reported the rela-
tion between hyperglycaemia and HbA1c and a higher risk
of HF, both in diabetic and non-diabetic patients [6-8].
This suggests that maintained hyperglycaemia plays an
important role as a myocardial deleterious agent [11] and
that advanced glycation is one of the main action mechan-
isms [10]. The role played by the AGE-RAGE axis in the
onset of HF has been studied [12,20,21], laying the foun-
dations for the link between hyperglycaemia and HF.
AGE levels increase in the context of maintained
hyperglycaemia [9] and they trigger intracellularTable 2 Glycaemic parameters association with diabetes
Diabetes N
Glucose (mg/dL) YES 52
NO 142
Fructosamine (mg/dL) YES 40
NO 101
HbA1c (%) YES 48
NO 121
AGE (AU) YES 52
NO 142
AGE: advanced glycation end products; HbA1c: glycated haemoglobin.signalling pathways that activate NF-κB transcription
factor, promoting oxidative stress [10], which also con-
tributes to AGE formation [11]. AGE lead to both dia-
stolic and systolic dysfunction [12]. There are three
reported molecular mechanisms for diastolic dysfunction
mediated by AGE: 1) AGE establish cross links between
matrix proteins decreasing their flexibility and promot-
ing myocardial stiffness [22]. 2) Through the activation
of their receptors (AGE-RAGE axis), AGE induce fibro-
sis by up-regulation of transforming growth factor beta
[23]. 3) AGE-RAGE axis activation also may influence
intracellular calcium homeostasis in cardiomyocytes, in-
creasing repolarisation period [24]. Regarding systolic
dysfunction, it stands out, by its clinical repercussion,
the acceleration of the coronary artery disease progres-
sion. AGE-RAGE interaction may induce atherosclerosis,
thrombosis and vasoconstriction [12]. AGE promote
endothelial dysfunction secondary to a reduced nitric
oxide bioavailability mediated by free radicals [25] and
they have shown to increase endothelial permeability
in vitro [26]. Endothelial dysfunction is involved in the
early stages of atherosclerosis and may trigger endothe-
lium repair by endothelial progenitor cells. However,
AGE have demonstrated to promote apoptosis and im-
pair functions of endothelial progenitor cells in culture
[27] and also to reduce growth and migration of mesen-
chymal stem cells [28]. AGE can establish cross links
with cholesterol-LDL particles resulting in the formation
of more atherogenic molecules by increasing their affin-
ity to macrophage receptors and enhancing foam cells
formation [29]. AGE may also induce systolic dysfunc-
tion by reducing intracellular calcium levels [24] whichMedia Standard deviation p
204.6 95.9 <0.001
134.0 53.2
254.9 85.4 <0.001
167.6 46.1
7.2 1.8 <0.001
5.6 0.8
67.3 60.8 0.132
53.5 37.1
Table 3 Patients’ characteristics according to high or low levels of early (HbA1c) or end (fluorescent AGE) glycation
products, considering median as cut off point
AGE HbA1c
HIGH LOW p HIGH LOW p
Demographic data
Age (years) 62.7 ± 14.7 62.9 ± 11.7 0.913 67.5 ± 12.5 58.1 ± 12.7 0.001
Female, % 22.9 26.5 0.560 28.9 21.5 0.272
Medical history
BMI (Kg/m2) 27.1 ± 3.6 26.9 ± 3.6 0.839 27.6 ± 4.0 26.2 ± 3.0 0.020
Current smoking, % 39.6 29.6 0.290 24.4 39.2 0.116
Diabetes, % 28.1 25.5 0.681 43.3 11.4 0.001
Hypertensión, % 55.2 40.8 0.045 60.0 35.4 0.001
Dyslipemia, % 51.0 38.0 0.086 51.1 32.9 0.017
On admission data
STEMI, % 45.8 58.2 0.086 48.9 53.2 0.579
Killip class ≥ II, % 11.5 16.3 0.327 18.9 8.9 0.062
Systolic blood pressure (mmHg) 137.9 ± 25.1 136.0 ± 27.8 0.603 141.2 ± 29.2 133.3 ± 22.2 0.050
Heart rate (bpm) 74.7 ± 18.3 75.7 ± 19.4 0.714 78.1 ± 19.8 72.2 ± 16.0 0.035
Atrial fibrillation, % 7.3 9.2 0.632 13.3 5.1 0.067
Haemoglobin (g/dL) 14.3 ± 1.8 14.4 ± 1.4 0.829 14.1 ± 1.7 14.5 ± 1.4 0.104
Leukocytes (103/μL) 10.6 ± 3.8 10.9 ± 4.1 0.622 10.5 ± 3.8 10.9 ± 4.1 0.453
Creatinine (mg/dL) 0.97 ± 0.15 0.93 ± 0.17 0.126 0.96 ± 0.15 0.94 ± 0.16 0.418
Laboratory parameters
TPI peak (ng/dL) 13.9 (6.4-70.1) 22.2 (4.5-69.4) 0.700 17.3 (6.2-85.6) 17.0 (5.1-63.2) 0.649
NT-proBNP (pg/mL) 783.0 (342.0-1712.7) 826.0 (376.5-1780.7) 0.348 1173.0 (450.2-2376.5) 568.5 (225.8-1235.2) 0.128
On admission data
STEMI, % 15.6 23.5 0.169 23.3 15.2 0.183
Killip class ≥ II, % 58.3 45.9 0.084 61.1 39.2 0.005
Abbreviations as in Table 1.
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Taken all these considerations into account, the AGE-
RAGE axis accelerates post-infarct myocardium remod-
elling, generating a deleterious feedback mechanism. In
fact, the relation between the rennin-angiotensin-
aldosterone system, a relevant system in ventricular re-
modelling and with demonstrated pathophysiological
implications, with AGE-RAGE axis has been suggested
[30]. So, angiotensin converting enzyme inhibitors and
angiotensin II receptor antagonists reduced plasma AGE
levels [31]. In contrast, it has been demonstrated that
AGE promote angiotensin II formation [32]. Other
possible ways to regulate AGE-RAGE axis activity have
been explored. The most physiological one would be to
increase physical activity in an attempt to reduce AGE-
RAGE axis activity. A preliminary study has shown a
reduction of soluble RAGE levels and an inverse cor-
relation between these levels and paraoxonase-1 activity
(an antioxidative enzyme) after an increasing physicalactivity intervention [33]. However, alagebrium, an AGE-
breaker, has not shown to improve physical exercise toler-
ance \and other secondary endpoints in patients with
heart failure in the BENEFICIAL clinical trial [34].
Even though, it is clear that AGE can play a role in
post-infarction HF, being crucial elements of ventricu-
lar remodelling. However, to our knowledge, this is the
first study to analyze the relationship between AGE
levels and post-infarction HF.
Therefore, it is reasonable to think that all the data re-
lating glycaemic and HbA1c with HF development risk
[5-8] could be explained based on the AGE-RAGE axis,
since the glucose-fructosamine-HbA1c pathway ends in
AGE [11] as pentosidine or carboxymethyl-lysine and
these molecules can mediate myocardial remodelling to-
wards cardiac dysfunction. In fact, in this study, glucose,
fructosamine and HbA1c were predictors of post-
infarction HF in the univariate analysis, but after the ad-
justment by confounding variables and AGE all of them
Figure 1 Levels of glucose, fructosamine, HbA1c and fluorescent AGE in patients who have suffered post-infarction HF during a
median follow-up of 1 year compared with patients who have not developed HF.
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dictive value is influenced by some of the other variables
(probably AGE).
Clinical implications
The higher level of AGE found in patients with post-
infarction HF showed the pathophysiological role that
these molecules can play in ventricular remodelling. This
means that, rather than a simple risk biomarker after an
acute myocardial infarction, AGE can be a new etio-
logical way to focus therapeutic research to reduce theTable 4 Eleven patients developed post-infarction HF in
the follow-up time indicated
Post-infarction HF (cases) Time of onset (days)
1 11
2 29
3 35
4 43
5 103
6 233
7 237
8 326
9 468
10 548
11 625harmful effects of remodelling. In fact, there are some
blockers of the AGE-RAGE axis that have been studied
in animals. The best known are aminoguanidine, an
AGE formation inhibitor [35], and alagebrium (ALT-
711), an AGE breaker [36]. Both molecules have been
tested in animals showing an improvement of myocar-
dial compliance [35] and an enhancement of cardiac
function in animals with contractile dysfunction [36].
The effect of alagebrium on diastolic dysfunction has
also been studied in humans [36,37]. In the DIAMONDTable 5 Results of the adjusted multivariate analysis for
prediction of HF development during the follow-up
period after myocardial infarction
Variables Hazard ratio CI 95% p
Age (years) 1.046 0.964 – 1.135 0.284
Diabetes mellitus 0.526 0.053 – 5.267 0.585
Heart rate (bpm) 1.012 0.971 – 1.054 0.572
LVEF ≤ 45% 1.643 0.251 – 10.758 0.605
Hb on admission (g/dL) 0.957 0.564 – 1.624 0.871
TPI peak (ng/dL) 1.006 1.001 – 1.011 0.025
NTproBNP (for 100 pg/mL) 1.030 1.006 – 1.054 0.015
HbA1c (%) 1.153 0.679 – 1.955 0.598
Fluorescent AGE (AU) 1.016 1.007 – 1.026 0.001
AGE: advanced glycation end products; Hb: haemoglobin; HbA1c: glycated
haemoglobin; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal
fragment of brain natriuretic peptide; TPI: troponin I.
Figure 2 Cumulative incidence curves for HF after acute
myocardial infarction for high and low levels of glycated
haemoglobin or fluorescent AGE, adjusted for age, diabetes
mellitus, systolic function, heart rate, haemoglobin levels,
troponin peak and NT-proBNP levels.
Raposeiras-Roubín et al. Cardiovascular Diabetology 2012, 11:102 Page 8 of 10
http://www.cardiab.com/content/11/1/102trial 23 stable patients with diastolic dysfunction were
treated with alagebrium. After 16 weeks, left ventricle
mass was reduced and diastolic function was improved
[37]. The PEDESTAL trial studied the effects of alageb-
rium in HF patients with depressed systolic function
(LVEF < 45%) and the preliminary results showed a ten-
dency to improve systolic function [38]. Our work opens
the field to study the possible role of AGE-RAGE axis
blockers in post-infarction HF development prevention.
Limitations
Despite the impact and enthusiasm that our results can
generate, we are aware of the limitations of our study and
they should be taken into account for the interpretation of
the results. Mainly, we must consider that our study popu-
lation, which included all patients admitted for acute cor-
onary syndrome in the coronary care unit within 15
months, was subjected to strict inclusion/exclusion criteria
to eliminate possible interfering variables, thus limiting the
extrapolation of our results to the real world of acute myo-
cardial infarction patients. On the other hand, this meant a
significant reduction in our sample size (n=194) and,considering it along with the inclusion of very selective
population with a lower cardiovascular risk, it determines
the statistical power of the analysis. Furthermore, some
analytical parameters were not determined in some of the
patients. Hence, AGE were measured in 100% population,
whereas HbA1c was measured in 87.2%, fructosamine in
72.7% and NT-proBNP in 79.4%. On the other hand, in our
study AGE were measured by Much’s method, which
means that an unspecified mixture of different fluorescent
AGE were detected in the measurement, but non-
fluorescent AGE were not considered. Despite all this, we
believe that our results maintain the pathophysiological and
clinical implications exposed and open the field to future
investigations.
Conclusions
AGE are independent biomarker for risk of post-
infarction HF. It can be presumed that the pathophysio-
logical base lays in the link between maintained hypergly-
caemia and ventricular remodelling. Future investigations
should confirm these findings and elucidate the patho-
physiological and therapeutic implications.
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